Stage 4 Cancer Vanishes After Rare Transplant

Automated laboratory equipment with robotic arms dispensing liquids into petri dishes

A mother’s routine ER visit for dehydration uncovered stage 4 colorectal cancer, but a friend’s liver donation turned her death sentence into no evidence of disease just three months later.

Story Snapshot

Amy Piccioli, 39-year-old LA mom of three, found asymptomatic stage 4 cancer via CT scan in May 2024.
After chemo shrank tumors, she received the first living-donor liver transplant at Northwestern Medicine from childhood friend Lauren Prior in December 2025.
Early 2026 scans show no evidence of disease, defying typical 13-14% five-year survival odds.
This breakthrough highlights hope for the 10-20% with liver-confined, chemo-responsive metastases.
Living-donor approach cuts wait times amid organ shortages, potentially reshaping protocols.

Diagnosis Shocks Silent Killer

Amy Piccioli entered the ER in May 2024 dehydrated from summer heat. Doctors ordered a CT scan, revealing a colon mass and liver lesions. Stage 4 colorectal cancer struck without warning—no bowel changes, family history, or symptoms. This silent progression affects 20-30% of cases diagnosed at this advanced stage. Piccioli, a CPA and mother of three, faced a dismal prognosis: median survival of 12-18 months with standard palliative chemo.

Treatment Path Forges Eligibility

June 2024 marked the start of chemotherapy and immunotherapy. Tumors shrank after three months, making Piccioli eligible for transplant consideration. Surgeons removed her colon tumor around September 2024. Northwestern Medicine’s multidisciplinary tumor board approved her—tumors unresectable yet responsive, confined to the liver. This strict criterion selects the 10-20% of patients who might benefit, contrasting typical guidelines barring stage 4 cases without five-year disease-free status.

Childhood Friend Steps Forward

Fall 2025 brought Lauren Prior, a 37-year-old mother of three from Glenview, Illinois, and Piccioli’s childhood family friend. Prior matched as a living donor after Piccioli shared her need with friends and family. In December 2025, dual surgeries at Northwestern Memorial Hospital unfolded. Prior donated 60% of her liver, which regenerates fully. Surgeons replaced Piccioli’s diseased liver entirely. Northwestern leads U.S. living-donor transplants, performing 40% of cases.

Rapid Recovery Signals Hope

Three months post-transplant in early 2026, Piccioli’s scans and blood tests detected no evidence of disease—no tumor molecules remained. She resumed workouts by month two, returning to normal life. Prior recovered fully too. Piccioli declared, “I have no evidence of disease currently… It’s amazing what the body can do.” Strict imaging every three months monitors recurrence risk in this pioneering case.

Breakthrough Challenges Norms

Dr. Dietch at Northwestern called it “lifesaving and potentially curative” for patients with limited options, stressing chemo response as the key selector. This first living-donor metastatic colorectal cancer transplant at the center validates trials showing 50-60% three-year survival versus under 10% without. Piccioli’s asymptomatic detection underscores screening urgency—20% reach stage 4 unnoticed.

Implications Reshape Futures

Short-term, living donors slash wait times versus deceased organs, boosting viability. Long-term, sustained no-evidence status could shift policies, challenging bans on cancer transplants pre-five-year remission. Annually, 150,000 U.S. metastatic colorectal cancer patients gain awareness of options. Costs near $1 million per transplant may save versus endless chemo, though lifelong monitoring persists. Northwestern expects donor recruitment surges and referrals.